Compare TLYS & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | ICCC |
|---|---|---|
| Founded | 1982 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 55.5M |
| IPO Year | 2012 | 1987 |
| Metric | TLYS | ICCC |
|---|---|---|
| Price | $1.45 | $6.08 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.25 | N/A |
| AVG Volume (30 Days) | ★ 48.6K | 21.4K |
| Earning Date | 03-11-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $545,742,000.00 | $27,769,304.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.18 | N/A |
| P/E Ratio | ★ N/A | $24.17 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $0.57 | $4.28 |
| 52 Week High | $4.40 | $7.60 |
| Indicator | TLYS | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.